RFA-DK-23-006: Advancing Research on Mechanisms and Management of Pain for Diseases and Conditions within NIDDK Mission Areas (R01 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on May 4, 2023.
From the official notice on Grants.gov, last changed February 10, 2023. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsOptional
- Funded byNIDDK
- Median yearly award$730,929
- Typical project length5 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under RFA-DK-23-006 were run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, 6 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DK-23-006 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-DK-22-005 | January 21, 2022 | Closed March 18, 2022 | Closed |
Key dates
| Posted | February 10, 2023 |
|---|---|
| Deadline | May 4, 2023 |
| Archived by Grants.gov | June 9, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The impact of pain on patient quality of life for diseases and conditions within the mission of the NIDDK is enormous. Despite prior research efforts, our understanding of the underlying biological and clinical contributors of pain remains limited. In addition, new clinical management strategies that better measure, predict, and target pain and improve upon current interventions, such as opioids, are critically needed. The current Funding Opportunity Announcement will address these needs through solicitation of broad investigator-initiated research projects proposing novel basic, translational, and clinical studies and efforts to develop new approaches to assess and treat pain for disorders within the NIDDK's mission. Investigations are expected to provide important new insights into the pathophysiology and clinical features of pain and foster new and improved treatment and pain management strategies for patients.
Funded under RFA-DK-23-006 so far
NIH funded 6 projects under RFA-DK-23-006 in fiscal 2023 to 2026, at 6 institutions. The median yearly award was $730,929.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Targeting visceral pain through intestinal neuropod cell GUCY2C signaling | Thomas Jefferson University | 2026 | $1.4 million |
| MECHANISMS OF VISCERAL PAIN DRIVEN BY SMALL INTESTINAL MICROBIOTA | Mayo Clinic Rochester | 2026 | $1.6 million |
| Sacral neuromodulation for the management of chronic pelvic pain | William Beaumont Hospital Research Inst | 2026 | $1.1 million |
| Role of neuron-satellite glia cell signaling in pelvic pain and visceral cross-sensitization | Albert Einstein College of Medicine | 2026 | $1.4 million |
| Functional and histological changes to peripheral innervation following spinal cord stimulation in patients with painful diabetic neuropathy | Ohio State University | 2026 | $1.5 million |
| Protein biomarkers to predict pain outcomes after total pancreatectomy with islet autotransplant | University of Minnesota | 2026 | $726,035 |
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before
From fiscal 2021 to 2025, Diabetes, Digestive, and Kidney Diseases Extramural Research (93.847) awarded $9.6 billion across 7,877 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 273 | $345 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 187 | $272 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 209 | $238 million |
| The Washington University | Missouri | 187 | $227 million |
| The Regents of the University of California, San Francisco | California | 176 | $208 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DK-23-006 still open?
No. It closed on May 4, 2023.
Who can apply for Advancing Research on Mechanisms and Management of Pain for Diseases and Conditions within NIDDK Mission Areas (R01 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Advancing Research on Mechanisms and Management of Pain for Diseases and Conditions within NIDDK Mission Areas (R01 Clinical Trial Optional)?
Closed May 4, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-DK-23-006?
NIH RePORTER lists 6 projects funded under RFA-DK-23-006 in fiscal 2023 to 2026, at 6 institutions. The most were at Thomas Jefferson University, Mayo Clinic Rochester, William Beaumont Hospital Research Inst.
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Trustees of the University of Pennsylvania, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 7,877 awards worth $9.6 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)